OncoMatch/Clinical Trials/NCT06347068
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Is NCT06347068 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including iC9-CAR.B7-H3 T Cell Therapy and cyclophosphamide for breast cancer.
Treatment: iC9-CAR.B7-H3 T Cell Therapy · cyclophosphamide · fludarabine — This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Required: HER2 (ERBB2) negative (ihc 0-1+ or fish ratio < 2.0)
Required: ESR1 negative (< 1% staining by ihc)
Required: PR (PGR) negative (< 1% staining by ihc)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of North Carolina · Chapel Hill, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06347068 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 negative is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify